- Home
- ANTA vs ELTX Comparison
ANTA vs ELTX Comparison
Compare ANTA & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | ELTX |
|---|---|---|
| Founded | 2022 | 2011 |
| Country | Singapore | United States |
| Employees | 113 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.7M | 185.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANTA | ELTX |
|---|---|---|
| Price | $8.02 | $9.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $16.17 | ★ $18.00 |
| AVG Volume (30 Days) | 1.7K | ★ 122.5K |
| Earning Date | 06-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | $21.95 | N/A |
| Revenue Next Year | $30.46 | N/A |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.25 | $5.80 |
| 52 Week High | $15.65 | $14.93 |
Technical Indicators
Market Signals| Indicator | ANTA | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 45.46 |
| Support Level | $6.53 | $9.70 |
| Resistance Level | $9.81 | $12.16 |
| Average True Range (ATR) | 0.52 | 0.97 |
| MACD | -0.12 | -0.08 |
| Stochastic Oscillator | 11.28 | 24.02 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.